{
    "Trade/Device Name(s)": [
        "Assure\u00ae Titanium Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Arkray, Inc.",
    "510(k) Number": "K200788",
    "Predicate Device Reference 510(k) Number(s)": [
        "K132121"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PZI"
    ],
    "Summary Letter Date": "June 14, 2021",
    "Summary Letter Received Date": "June 15, 2021",
    "Submission Date": "June 14, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine",
        "POCT"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [
        "Single-use, auto-disabling lancing device"
    ],
    "Instrument(s)/Platform(s)": [
        "Assure\u00ae Titanium Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electro-chemical biosensor",
        "Amperometric detection"
    ],
    "Methodologies": [
        "Quantitative measurement",
        "Biosensor technology"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strips",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Assure\u00ae Titanium Blood Glucose Monitoring System for quantitative measurement of glucose in capillary whole blood using a biosensor meter and test strips",
    "Indications for Use Summary": "Quantitative measurement of glucose in fresh capillary whole blood from the fingertips for point of care use in endocrinology clinics and nursing or skilled nursing facilities; for determining dysglycemia, not for diabetes diagnosis, neonatal use, or acute care/hospital settings; prescription use only",
    "fda_folder": "Clinical Chemistry"
}